HeartSciences Inc. filed a Form 8-K on November 19, 2026, disclosing that the company entered into an Equity Distribution Agreement with Maxim Group LLC on November 18, 2026, to conduct an at-the-market offering of common stock.

Key Highlights

  • At-the-market agreement: HeartSciences entered into an Equity Distribution Agreement with Maxim Group LLC as sales agent on November 18, 2026.
  • Prospectus Supplement offering size: Due to Form S-3 limitations, the Prospectus Supplement covers shares with an aggregate offering price of up to $3,077,649.
  • EDA maximum: The Equity Distribution Agreement itself provides for the sale of up to $50,000,000 of common stock, $0.001 par value per share.
  • Commission structure: HeartSciences will pay Maxim Group a commission of 2.5% of gross sales price per share while subject to General Instruction I.B.6 of Form S-3, and 2.0% thereafter.
  • Pending merger: On June 23, 2026, HeartSciences entered into a definitive merger agreement with Fortitude Mining Holdings, Inc., described as "a vertically-integrated digital asset mining platform anchored in Zcash," in an all-stock transaction.
  • Shelf registration effective: The company's Form S-3 Registration Statement (File No. 333-299147) was declared effective by the SEC on November 17, 2026.

HeartSciences Establishes At-the-Market Equity Program with Maxim Group

According to the filing, HeartSciences Inc. (NASDAQ:HSCS), a Texas-incorporated company headquartered in Southlake, Texas, entered into the Equity Distribution Agreement with Maxim Group LLC on November 18, 2026. Under the EDA, shares of the company's common stock may be sold from time to time through or to Maxim Group acting as sales agent or principal. The filing states that sales may be made "by any method permitted by law deemed to be an 'at the market offering,'" and that Maxim Group may also sell shares by any other method permitted by law, including negotiated transactions, with the company's prior written consent.

The filing notes that although the EDA provides for sales of up to $50,000,000 of shares, the actual offering capacity covered by the Prospectus Supplement is capped at an aggregate offering price of up to $3,077,649. The company disclosed that this limit results from General Instruction I.B.6 of Form S-3, which restricts issuers whose aggregate market value of non-affiliate-held common shares is below $75 million from selling, in a public primary offering, securities with a value exceeding one-third of that aggregate market value in any 12-month period. The company will also reimburse Maxim Group for legal fees and expenses up to $15,000 in connection with entering into the EDA, plus up to $5,000 per Bringdown Date as defined in the agreement.

The filing also discloses that on June 23, 2026, HeartSciences entered into a definitive merger agreement with Fortitude Mining Holdings, Inc. to combine in an all-stock transaction. The company reported that a definitive proxy statement on Schedule 14A was filed with the SEC on October 19, 2026, and mailed to shareholders entitled to vote at the related special meeting. The filing states that communications related to both companies and the proposed transaction "may be deemed solicitation material" in respect of that transaction.

What Was Disclosed

HeartSciences disclosed entry into an at-the-market Equity Distribution Agreement with Maxim Group LLC, covering common stock sales of up to $3,077,649 under the current Prospectus Supplement, alongside a reminder that a merger agreement with Fortitude Mining Holdings, Inc. remains pending.